<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04795856</url>
  </required_header>
  <id_info>
    <org_study_id>R20-178</org_study_id>
    <nct_id>NCT04795856</nct_id>
  </id_info>
  <brief_title>Understanding the Metabolic and Functional Derangement of Primary Mitral Regurgitation: a Feasibility Study Using Carbon 11(C-11) Acetate Cardiac Positron Emission Tomography Magnetic Resonance Imaging (PET-MRI)</brief_title>
  <official_title>Understanding the Metabolic and Functional Derangement of Primary Mitral Regurgitation: a Feasibility Study Using C-11 Acetate Cardiac PET-MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this pilot imaging study is to investigate the underlying changes in myocardial&#xD;
      oxidative metabolism, myocardial inflammation and alterations in extracellular volume in&#xD;
      patients with chronic compensated moderate-severe primary mitral regurgitation (PMR). The PET&#xD;
      tracer [11C] acetate will be used to image and quantify myocardial oxygen consumption (MVO2)&#xD;
      in hearts of the study participants. Cardiac magnetic resonance imaging (CMR) using a&#xD;
      gadolinium-based contrast agent (GBCA) will be performed to assess for and quantify expansion&#xD;
      of myocardial extracellular volume (ECV) and myocardial inflammation. We will enroll a total&#xD;
      of 12 participants, nine of whom will be patients with chronic, compensated asymptomatic&#xD;
      moderate-severe PMR evaluated at the UAB Cardiovascular Disease and Structural Valve Clinic&#xD;
      and three normal control subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 31, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2024</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The healthy group will establish a baseline for the moderate- severe mitral valve regurgitation (PMR) group.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantitatively correlate metabolic findings from the PET component with quantitative T1 and T2 parametric mapping from the cardiac MR component of the hybrid PET-MR study.</measure>
    <time_frame>0-48 hours</time_frame>
    <description>Parametric analysis of T1 and T2 mapping will be performed using dedicated software (Qmap, Medis).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Mitral Valve Regurgitation</condition>
  <arm_group>
    <arm_group_label>chronic compensated moderate-severe primary mitral regurgitation (PMR)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[11C] acetate</intervention_name>
    <description>PET Tracer</description>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_label>chronic compensated moderate-severe primary mitral regurgitation (PMR)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age.&#xD;
&#xD;
          -  Patients with chronic, asymptomatic, compensated PMR evaluated in the UAB Structural&#xD;
             Valve Clinic OR Normal controls identified from a normal aged matched population.&#xD;
&#xD;
          -  Negative urine or serum Î²-human chorionic gonadotropin (hcg) test within 48 hours of&#xD;
             [11C] acetate administration in women of childbearing potential. Women who are&#xD;
             post-menopausal with at least 1 year since last menses or documented surgical&#xD;
             sterilization will not require pregnancy testing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Inability to lie still for the imaging study&#xD;
&#xD;
          -  Weight exceeding the weight limit of the PET imaging table (500 pounds)&#xD;
&#xD;
          -  Comorbidities including any of the following: history of coronary artery disease,&#xD;
             prior coronary revascularization, prior myocardial infarction, prior open sternotomy,&#xD;
             history of congestive heart failure, history of non-ischemic cardiomyopathy including&#xD;
             dilated, restrictive, hypertrophic, amyloid heart disease, cardiac sarcoidosis,&#xD;
             history of hypertension, diabetes mellitus, chronic kidney disease with a glomerular&#xD;
             filtration rate (GFR) less than 60 ml/min/1.73 m2 , history of other valvular heart&#xD;
             disease defined as mitral stenosis, aortic stenosis, more than mild aortic&#xD;
             regurgitation, more than mild tricuspid regurgitation, history of more than mild&#xD;
             pulmonary hypertension and history of cancer with exposure to chemotherapy or&#xD;
             radiotherapy.&#xD;
&#xD;
          -  Contraindication for gadolinium-based contrast agent, ProHance (gadoteridol)&#xD;
&#xD;
          -  Contraindication for MRI study (e.g. non-removable metal implants or certain tattoos)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pradeep Bhambhvani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sebastian Eady</last_name>
    <phone>205-996-2636</phone>
    <email>smeady@uabmc.edu</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 9, 2021</study_first_submitted>
  <study_first_submitted_qc>March 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Pradeep Bhambhvani, MD</investigator_full_name>
    <investigator_title>Professor, Division of Molecular Imaging and Therapeutics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

